Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137880 | 0.80 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL1091686 | 0.73 | NPSR1 (0.41) | NPSR1 | |
| SCHEMBL24172013 | 0.73 | TSHR (0.37) | — | |
| SCHEMBL4346571 | 0.72 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL4536488 | 0.72 | — | — | |
| SCHEMBL10101623 | 0.72 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL823098 | 0.72 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL19031082 | 0.71 | CYP2D6 (0.32) | — | |
| SCHEMBL22851082 | 0.71 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL13537617 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2023-03-09 | — | — | US | disclosed |
| US-11530194-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210214342-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | SERENEX, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7358370-B2 | Anticancer, inflammation, arthritis, angiogenesis, neurodegenerative diseases, fungal infections, malaria; Heat-shock protein 90 inhibitors; 4-(6,6-Dimethyl-4-oxo-3-methyl-4,5,6,7-tetrahydro-indazol-1-yl)-2-(3,4,5-trimethoxyanilino)-benzamide | SERENEX, INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070269405-A1 | Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2007-11-22 | — | — | US | disclosed |
| US-20070269405-A1 | Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2007-11-22 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC (US) | 2007-03-08 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | NPSR1 4598/4885 |
| US-20230295179-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | NPSR1 4077/4885 |
| US-20230071483-A1 | EIF4A-INHIBITING COMPOUNDS AND METHODS RELATED THERETO | EIF4A1, EIF4A2, EIF4A3 | NPSR1 4077/4885 |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | NPSR1 10/4885 |
| US-20070269405-A1 | Androgen Receptor Modulators | AR, SHBG, FSHR | NPSR1 1387/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | NPSR1 3129/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | NPSR1 10/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | NPSR1 1991/4885 |
| US-20080096887-A1 | cell proliferation, such as cancer, inflammation, and angiogenesis; fungal infections; antimalaria; Heat hock protein 90 (HSP-90) inhibitor | HSP90AA1, HSP90AB1, HSPA4 | NPSR1 2162/4885 |
| US-11530194-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | NPSR1 2721/4885 |
| US-20070054933-A1 | 17-Heterocyclic-4-azasteroid derivatives as androgen receptor modulators | AR, SHBG, NR5A1 | NPSR1 1751/4885 |
| US-20210214342-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | NPSR1 2721/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | NPSR1 13/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | NPSR1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.